RDEA594: Phase IIa data

Data from the second cohort of a Phase IIa trial in 6 patients showed that the addition of 400 mg RDEA594 to allopurinol reduced serum urate levels by an additional 24% vs. allopurinol alone. Allopurinol alone reduced serum urate levels by 39% from baseline after 1 week. The addition of 200 mg RDEA594 to allopurinol in the second week led to a reduction in serum urate levels of 48% from baseline and increasing the dose of RDEA594 to 400 mg plus allopurinol in the third week led to a reduction in serum urate levels of 54% from baseline. Responses, defined as achieving a target serum urate level of <6 mg/dL, were achieved in 50% of patients after week 1 and 100% of patients after weeks 2 and 3. The combination was well tolerated. ...